The patent, titled "Compositions Comprising Enzyme-Cleavable Prodrugs and Controlled Release Nafamostat and Methods of Use Thereof", includes both composition-of-matter and method-of-use claims that strengthen Ensysce's intellectual property estate for its unique overdose protection platform. The new issuance provides protection for the Company's MPAR® patent coverage through 2042 in this jurisdiction and expands the United States Patent No. 12,599,578 that issued on April 14, 2026.

MPAR®, which has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA), is engineered to reduce the impact of opioid exposure during an overdose. In clinical studies, PF614-MPAR provided effective pain relief when used as directed, while preventing excessive opioid release when multiple doses were taken. Ensysce has extended its MPAR® technology beyond opioids to other drug classes such as amphetamines and methadone to support the development of safer treatments for pain, ADHD, and opioid use disorder.